With over two decades of experience shaping intellectual property strategies in the pharmaceutical and life sciences industries, Mr. Grumbling is a seasoned patent attorney whose deep expertise spans both in-house and private practice. His experience spans all aspects of IP counseling, including preparation and prosecution, IP diligence and risk management, freedom-to-operate analyses, patent opinions, Paragraph IV letters, infringement complaints, and negotiating and drafting IP licenses and settlement agreements.
Industry Experience
Mr. Grumbling started his professional career at United States Patent and Trademark Office, where he applied his chemical expertise as a patent examiner in the art of small molecule heterocyclic chemistry, attaining the level of Primary Examiner.
Honors/Distinctions
• Advisory Board Member, Spark Surprise AZ
• Advisory Board Member, BioAccel
• President, Estrella Rotary, Goodyear Arizona
• Able Toastmaster
Professional Activities
Mr. Grumbling brings extensive private practice experience advising clients at every stage of growth — from innovative startups to Fortune 50 industry leaders. He offers deep technical insight across the pharmaceutical and biologics landscape, encompassing small molecules, oligonucleotides, monoclonal antibodies, and antibody–drug conjugates. His work spans a broad range of therapeutic areas, including women’s health, neurology, seizure and gastroparesis disorders, cardiovascular disease, antivirals, and oncology. A trusted advisor to his clients, Mr. Grumbling provides strategic counsel on patent drafting and acquisition, licensing, and global patent procurement and prosecution strategies.
Mr. Grumbling has a proven record of delivering IP strategies that create real business value. He has helped clients secure pivotal intellectual property rights that have underpinned successful multimillion-dollar transactions — including public stock offerings and mergers and acquisitions valued from over $10 million to $1.3 billion. His experience encompasses a wide range of technologies, including injectable pharmaceuticals, transdermal drug-delivery systems, artificial skin prosthetics, therapeutics for Alzheimer’s and Parkinson’s diseases, and cancer chemotherapies.